Japan’s Otsuka Holdings priced shares in its $2.4 billion initial public offering (IPO), 2nd-biggest Japan IPO this year after Dai-ichi Life, at the lower end of its range, reflecting investors’ concern about the Japanese drug maker’s growth potential. Chief Executive Officer Tatsuo Higuchi, Japan’s second-biggest pharmaceutical group in terms of annual revenue after Takeda Pharmaceutical, said [...]